Edgewise Therapeutics, Inc. (EWTX)
| Previous close | 17.39 |
| Open | 17.77 |
| Bid | 17.24 x 200 |
| Ask | 17.49 x 100 |
| Day's range | 17.15 - 17.84 |
| 52-week range | 5.12 - 21.60 |
| Volume | |
| Avg. volume | 603,664 |
| Market cap | 1.625B |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
BOULDER, Colo., May 10, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.
- Business Wire
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
BOULDER, Colo., May 09, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights.
- Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
BOULDER, Colo., May 07, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles.
